Organogenesis Holdings Q3 2026 earnings

ORGO · 2026-11-05 16:10 AMC ET · 8-K on SEC

Revenue increased sequentially but remains down sharply YoY; adjusted loss widened despite expense cuts.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$45.5M-70%+6.4%Ex. 99.1, Financial Results Summary

Revenue breakdown

SegmentActualYoYShare of revenueNote
Advanced Wound Care$38.2M-73%84%Revenue decline of $103.3M
Surgical & Sports Medicine$7.3M-19%16%Revenue decline of $1.7M

Margins and costs

  • Gross margin 52% (prior 76%, change -24 pp)
  • Operating expenses $74.9M (-42% YoY)
  • One-offs in the quarter Restructuring charge $0.5M; Fair value adjustment to assets held for sale $0.9M
  • Effective tax rate 0% (prior-year 2%, year-to-date 20%)
  • Non-GAAP bridge Adds back stock-based compensation, inventory write-downs, restructuring, fair value adjustment, and R&D program termination costs.

KPIs

MetricActualPrior quarterPrior yearChange
Cash, cash equivalents and restricted cash$26.9M$46.8M$94.3M-$19.9M
Weighted-average common shares outstanding128.99M128.67M126.85M+0.32M

Guidance

MetricGuidePrior guideChange
Total net revenue$179.4M - $200.0M$179.0M - $215.0MLowered midpoint by $5.3M

What drove it

  • Revenue story Revenue increased sequentially (+$2.7M) driven by Advanced Wound Care (+$2.1M) and Surgical & Sports Medicine (+$0.6M), but remains down 70% YoY.
  • EPS story Net loss widened due to a $51.2M increase in loss, driven by lower revenue and higher operating expenses.
  • One-off check Restructuring charge $0.5M; Fair value adjustment to assets held for sale $0.9M

The good

  • Revenue increased sequentially
  • Operating expenses decreased 42% YoY

The bad

  • Revenue down 70% YoY
  • Adjusted loss widened YoY
  • Cash balance down $19.9M QoQ

The ugly

  • none

Open questions

  • What specific factors drove the sequential revenue increase?
  • How will the company sustain operations with $26.9M in cash?
Full release

Organogenesis Holdings (ORGO) earnings release, November 5, 2026

Organogenesis Holdings Inc. (ORGO) · Form 8-K, Item 2.02 · Filed · SEC filing

Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results

CANTON, Mass.,

(November 5, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Financial Results Summary:

• Net revenue of $45.5 million for the third quarter of 2026, a decrease of $105.0 million compared to net revenue of $150.5 million for the third quarter of 2025. Net revenue for the third quarter of 2026 consists of: o

Net revenue from Advanced Wound Care products of $38.2 million, a decrease of 73% from the third quarter of 2025. o

Net revenue from Surgical & Sports Medicine products of $7.3 million, a decrease of 19% from the third quarter of 2025.

• Net loss of $29.6 million for the third quarter of 2026, compared to net income of $21.6 million for the third quarter of 2025, an increase in net loss of $51.2 million.

• Adjusted net loss of $29.3 million for the third quarter of 2026, compared to adjusted net income of $23.2 million for the third quarter of 2025, an increase in adjusted net loss of $52.5 million.

• Adjusted EBITDA loss of $22.4 million for the third quarter of 2026, compared to Adjusted EBITDA income of $30.1 million for the third quarter of 2025, an increase in Adjusted EBITDA loss of $52.5 million.

“We continue to strengthen our position as a leader in regenerative medicine as customers choose a partner and products they trust,” said Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis. “Third quarter revenue increased sequentially, and our market share gains are broad-based across our portfolio. We are defining a sustainable future for advanced wound care as we emerge from the market reset a stronger company anchored by evidence-based living cell products that we believe will be the cornerstone of the market going forward.”

Third Quarter 2026 Financial Results:

Net product revenue for the third quarter of 2026 was $45.5 million, compared to $150.5 million for the third quarter of 2025, a decrease of $105.0 million, or 70%. The decrease in net product revenue was driven by a decrease of $103.3 million, or 73%, in net product revenue for Advanced Wound Care products.

Gross profit for the third quarter of 2026 was $23.6 million, or 52% of net product revenue, compared to $114.2 million, or 76% of net product revenue for the third quarter of 2025, a decrease of $90.7 million, or 79%.

Operating expenses for the third quarter of 2026 were $74.9 million compared to $130.1 million for the third quarter of 2025, a decrease of $55.2 million, or 42%. Cost of goods sold was $21.9 million for the third quarter of 2026, compared to $36.3 million for the third quarter of 2025, a decrease of $14.4 million, or 40%.

Selling, general and administrative expenses were $45.1 million for the third quarter of 2026, compared to $79.7 million for the third quarter of 2025, a decrease of $34.7 million, or 43%. R&D expense was $8.0 million for the third quarter of 2026, compared to $13.2 million for the third quarter of 2025, a decrease of $5.3 million, or 40%.

Operating loss for the third quarter of 2026 was $29.5 million, compared to an operating income of $20.7 million for the third quarter of 2025, an increase in operating loss of $50.2 million.

Total other expense, net, for the third quarter of 2026 was $0.1 million, compared to total other income, net, of $0.4 million for the third quarter of 2025, a decrease of $0.6 million.

Net loss for the third quarter of 2026 was $29.6 million, or $(0.25) per share, compared to net income of $21.6 million, or $0.11 per share, for the third quarter of 2025, an increase in net loss of $51.2 million, or $(0.36) per share.

Adjusted net loss was $29.3 million for the third quarter of 2026, compared to adjusted net income of $23.2 million for the third quarter of 2025, an increase in adjusted net loss of $52.5 million.

Adjusted EBITDA loss was $22.4 million for the third quarter of 2026, compared to Adjusted EBITDA income of $30.1 million for the third quarter of 2025, an increase in Adjusted EBITDA loss of $52.5 million.

Non-GAAP operating loss was $29.1 million for the third quarter of 2026, compared to non-GAAP operating income of $23.0 million for the third quarter of 2025, an increase in non-GAAP operating loss of $52.1 million.

Nine Months Ended September 30, 2026 Financial Results:

Net product revenue for the nine months ended September 30, 2026 was $124.5 million, compared to $338.0 million for the nine months ended September 30, 2025, a decrease of $213.4 million, or 63%. The decrease in net product revenue was driven by a decrease of $210.3 million, or 67%, in net product revenue for Advanced Wound Care products.

Gross profit for the nine months ended September 30, 2026 was $53.2 million, or 43% of net product revenue, compared to $250.4 million, or 74% of net product revenue for the nine months ended September 30, 2025, a decrease of $197.2 million, or 79%.

Operating expenses for the nine months ended September 30, 2026 were $275.8 million compared to $357.2 million for the nine months ended September 30, 2025, a decrease of $81.3 million, or 23%. Cost of goods sold was $71.3 million for the nine months ended September 30, 2026, compared to $87.6 million for the nine months ended September 30, 2025, a decrease of $16.3 million, or 19%.... (truncated)ion, or 27%. R&D expense was $41.4 million for the nine months ended September 30, 2026, compared to $34.3 million for the nine months ended September 30, 2025, an increase of $7.2 million, or 21%.

Operating loss for the nine months ended September 30, 2026 was $149.4 million, compared to an operating loss of $18.6 million for the nine months ended September 30, 2025, an increase in operating loss of $130.8 million.

Total other income, net, for the nine months ended September 30, 2026 was $0.4 million, compared to $2.1 million for the nine months ended September 30, 2025, a decrease of $1.7 million.

Net loss for the nine months ended September 30, 2026 was $179.1 million, or $(1.47) per share, compared to net loss of $6.7 million, or $(0.12) per share, for the nine months ended September 30, 2025, an increase in net loss of $172.4 million, or $(1.35) per share.

Adjusted net loss was $162.1 million for the nine months ended September 30, 2026, compared to adjusted net income of $2.3 million for the nine months ended September 30, 2025, an increase in adjusted net loss of $164.4 million.

Adjusted EBITDA loss was $104.9 million for the nine months ended September 30, 2026, compared to Adjusted EBITDA income of $14.0 million for the nine months ended September 30, 2025, an increase in Adjusted EBITDA loss of $118.9 million.

Non-GAAP operating loss was $126.1 million for the nine months ended September 30, 2026, compared to non-GAAP operating loss of $6.3 million for the nine months ended September 30, 2025, an increase in non-GAAP operating loss of $119.8 million.

As of September 30, 2026, the Company had $26.9 million in cash, cash equivalents and restricted cash and no outstanding debt obligations, compared to $94.3 million in cash, cash equivalents and restricted cash and no outstanding debt obligations as of December 31, 2025.

Fiscal Year 2026 Outlook:

For the year ending December 31, 2026, the Company now expects:

• Total net revenue between $179.4 million and $200.0 million, representing a decline in the range of 65% to 68%, as compared to total net revenue of $564.2 million for the year ended December 31, 2025. o

Our updated total revenue guidance continues to reflect the expectation that we see sequential improvement in our revenue trends in the fourth quarter, however, at a more measured rate versus what our prior guidance assumed, resulting in a second half revenue decline in the range of approximately 68% to 74% year over year, and compared to our prior guidance range which assumed a decline in the range of 64% to 74% year-over-year.

Third Quarter Earnings Conference Call:

Management will host a conference call at 5:00 p.m. Eastern Time on November 5th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.

ORGANOGENESIS HOLDINGS INC.

UNAUDITED CONDENSED CONSOLIDATED BA

LANCE SHEETS

(amounts in thousands, except share and per share data)

Financial statements

Income Statement

Three Months Ended September 30, — (amounts in thousands, except share and per share data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenue:
Net product revenue45,457150,487124,512337,959
Grant income3771,928603
Total revenue45,457150,864126,440338,562
Operating expenses:
Cost of goods sold21,89836,25171,34387,604
Selling, general and administrative45,08779,743164,238226,062
Research and development7,96113,22141,41934,256
Fair value adjustment to assets held for sale922-1,1889,235
Total operating expenses74,946130,137275,812357,157
Income (loss) from operations-29,48920,727-149,372-18,595
Other income (expense), net:
Interest income (expense), net-614154572,045
Other income (expense), net-7118-5993
Total other income (expense), net-1324333982,138
Net income (loss) before income taxes-29,62121,160-148,974-16,457
Income tax benefit (expense)-8407-30,0789,789
Net income (loss) and comprehensive income (loss)-29,62921,567-179,052-6,668
Accretion of redeemable convertible preferred stock to redemption value-181-140-510-390
Cumulative dividend on redeemable convertible preferred stock-2,959-2,734-8,705-8,042
Undistributed earnings allocated to participating redeemable convertible preferred stock-4,168
Net income (loss) attributable to common stockholders-32,76914,525-188,267-15,100
Net income (loss) per share:
Basic-0.250.11-1.47-0.12
Diluted-0.250.11-1.47-0.12
Weighted-average common shares outstanding:
Basic128,990,436126,881,709128,489,389126,679,109
Diluted128,990,436130,848,995128,489,389126,679,109

Income Statement

Three Months Ended September 30, — The following table presents a reconciliation of GAAP income (loss) from operations to non-GAAP operating income (loss), for the periods presented: (in thousands)

Three Months Ended September 30, – 2026 – (Unaudited, in thousands)Three Months Ended September 30, – 2025 – (Unaudited, in thousands)Nine Months Ended September 30, – 2026 – (Unaudited, in thousands)Nine Months Ended September 30, – 2025 – (Unaudited, in thousands)
Income (loss) from operations-29,48920,727-149,372-18,595
Amortization of intangible assets (1)4338426,5742,525
Inventory write-downs (2)3,327
Restructuring charge (3)5168,957516
Fair value adjustment to assets held for sale (4)922-1,1889,235
R&D program termination costs (5)5,588
Non-GAAP operating income (loss)-29,05623,007-126,114-6,319

Balance Sheet

September 30, — (amounts in thousands, except share and per share data)

September 30, – 2026December 31, – 2025
Current assets:
Cash and cash equivalents21,32693,679
Restricted cash163652
Accounts receivable, net92,687217,451
Inventories, net26,68329,627
Asset held for sale2,425
Prepaid expenses and other current assets17,26818,354
Total current assets158,127362,188
Property and equipment, net98,600103,711
Intangible assets, net2,5719,145
Goodwill28,77228,772
Operating lease right-of-use assets, net47,80855,749
Deferred tax asset, net29,962
Other assets33,0279,203
Total assets368,905598,730
Current liabilities:
Current portion of finance lease obligations8979,435
Current portion of operating lease obligations - related party4,8464,258
Current portion of operating lease obligations3,5694,949
Accounts payable22,47831,949
Accrued expenses and other current liabilities15,85949,533
Total current liabilities47,649100,124
Finance lease obligations, net of current portion10,37212,788
Operating lease obligations, net of current portion - related party24,47228,237
Operating lease obligations, net of current portion20,36022,470
Other liabilities3,3111,193
Total liabilities106,164164,812
Commitments and contingencies (Note 15)
Series A redeemable convertible preferred stock, $0.0001 par value; 130,000 shares authorized, issued and outstanding; liquidation preference of $150,922 and $142,217 at September 30, 2026 and December 31, 2025, respectively.143,004133,789
Stockholders’ equity:
Common stock, $0.0001 par value; 400,000,000 shares authorized; 130,522,276 and 127,680,424 shares issued; 129,793,728 and 126,951,876 shares outstanding at September 30, 2026 and December 31, 2025, respectively.1313
Additional paid-in capital302,164303,194
Accumulated deficit-182,440-3,078
Total stockholders’ equity119,737300,129

Cash Flow

Nine Months Ended September 30, — (amounts in thousands, except share and per share data)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities:
Net loss-179,052-6,668
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization11,76911,207
Amortization of intangible assets6,5742,525
Reduction in the carrying value of right-of-use assets7,0716,193
Non-cash interest expense211208
Deferred tax expense (benefit)29,962-6,129
Provision recorded for credit losses1,1615,403
Loss on disposal of property and equipment72373
Adjustment for excess and obsolete inventories12,6397,963
Stock-based compensation9,4948,974
Fair value adjustment to assets held for sale-1,1889,235
Changes in operating assets and liabilities:
Accounts receivable123,603-64,325
Inventories-14,746-14,954
Prepaid expenses and other current assets and other assets6,924-3,298
Operating leases-5,798-6,302
Accounts payable-6,922643
Accrued expenses and other current liabilities-31,731-1,943
Other liabilities1861,466
Net cash used in operating activities-29,120-49,729
Cash flows from investing activities:
Purchases of property and equipment-5,712-9,499
Sale of asset held for sale3,612
Net cash used in investing activities-2,100-9,499
Cash flows from financing activities:
Payments of withholding taxes in connection with RSUs vesting-3,050-1,798
Proceeds from the exercise of stock options155
Principal repayments of finance lease obligations-10,598-869
Issuance of common stock in connection with the ATM facility, net of offering costs1,432
Construction of landlord assets, net of tenant allowance-23,958-10,039
Net cash used in financing activities-36,174-12,551
Change in cash, cash equivalents and restricted cash-67,394-71,779
Cash, cash equivalents, and restricted cash, beginning of period94,331136,151
Cash, cash equivalents, and restricted cash, end of period26,93764,372
Supplemental disclosure of cash flow information:
Cash paid for income taxes$—4,086
Supplemental disclosure of non-cash investing and financing activities:
Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock9,2158,432
Change in purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities-236-2,029
Right-of-use assets obtained through finance lease obligations-3572,282
Right-of-use assets obtained through operating lease obligations$—2,388
Deemed dividend for anti-dilution adjustment to convertible preferred stock310$—
Landlord asset additions included in accounts payable and accrued expenses and other current liabilities, net of tenant allowances2,9091,925

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.